Abstract
Testosterone Therapy in Men with Advanced Prostate Cancer: Too Many Unknowns for Safe Use.
Highlights
Accepted practice surrounding the use of exogenous testosterone in the presence of treated or untreated localized prostate cancer has changed dramatically over the past decade
Recent evidence has failed to show an increased risk of de novo disease in the general population,[1] or of progression or recurrence in men after definitive therapy or on active surveillance for localized disease.[2]. This has culminated in recent American Urological Association guidelines on testosterone therapy (TT) reinforcing the lack of evidence connecting TT to de novo prostate cancer, and supporting the safety of TT in men with treated prostate cancer—primarily in men with low or intermediate risk disease.[1]
TT in men with biochemical recurrence and metastatic prostate cancer: initial observations by Morgentaler et al.,[4] the authors recognize the lack of evidence in men with advanced disease, the morbidity caused by androgen deprivation, and hypothesize that based on prior evidence in localized disease, that testosterone in these men may be safe
Summary
Accepted practice surrounding the use of exogenous testosterone in the presence of treated or untreated localized prostate cancer has changed dramatically over the past decade. Recent evidence has failed to show an increased risk of de novo disease in the general population,[1] or of progression or recurrence in men after definitive therapy or on active surveillance for localized disease.[2] This has culminated in recent American Urological Association guidelines on testosterone therapy (TT) reinforcing the lack of evidence connecting TT to de novo prostate cancer, and supporting the safety of TT in men with treated prostate cancer—primarily in men with low or intermediate risk disease.[1]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have